Skip to content

The conventional in-vitro fertilization embryo for preimplantation genetic testing for aneuploidies (PGT-A) : a randomised controlled mutli-centric trial

The conventional in-vitro fertilization embryo for preimplantation genetic testing for aneuploidies (PGT-A) : a randomised controlled mutli-centric trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072379
Enrollment
Unknown
Registered
2023-06-12
Start date
2023-06-16
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-male factor infertility

Interventions

Control:use of ICSI in PGT-A cycles
Trial:use of conventional IVF in PGT-A cycles

Sponsors

Henan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
38 Years to 40 Years

Inclusion criteria

Inclusion criteria: To be eligible to participate in the trial, subjects must meet all of the following criteria: (1) Eligible for IVF, PGT-A cycle patients; (2) At least six oocytes obtain following oocyte retrieval after ovulation induction treatment; (3) Femal age = 40 years, 18kg/m2 = BMI =30kg/m2; (4) The male semen index was normal (semen concentration >5×10^6/mL,number of progressive sperm =5×10^6);

Exclusion criteria

Exclusion criteria: Participants were excluded from the trial if they meet any of the following criteria: (1) IVF or ICSI contraindicated patients: patients with type ? and type ? diabetes mellitus; Patients with undiagnosed liver diseases or functional disorders; Kidney disease or abnormal serum renal function; Anemia; A history of deep vein thrombosis, pulmonary vein thrombosis, or cerebrovascular accident; Uncontrolled hypertension or symptomatic heart disease; Have or suspected history of cervical cancer, endometrial cancer, breast cancer; Unexplained vaginal bleeding; (2) Male factor infertility: severe oligospermia, asthenospermia, teratospermia; (3) Low fertilization rate in previous cycles (fertilization rate <25%); (4) Oocytes and sperm donor patients; (5) Patients using frozen sperm;

Design outcomes

Primary

MeasureTime frame
The euploid rate;Partenal contamination analysis;

Secondary

MeasureTime frame
Proportion of aneuploid blastocyst;Fertility rate;Rate of embryo degeneration;Proportion of mosaic (mosaic rate of 30%-70%);Proportion of deletion/duplication blastocyst(>4Mb);Grade of D3/D5 blastocysts morphology;Blastocysts formation rate;Number of euploid blastocyst available for transfer;

Countries

China

Contacts

Public ContactZhang Cuilian

Henan Provincial People's Hospital

17051337409@163.com+86 199 3767 1914

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026